Exosome Diagnostics, based in Cambridge (MA) and Martinsried near Munich, has announced the launch of the world’s first liquid biopsy designed to isolate and analyze exosomal RNA from a blood sample. The test ExoDx™ Lung(ALK) detects therapy-relevant EML4-ALK mutations in patients with non-small cell lung cancer (NSCLC). The goal is to support clinician’s individualised treatment decisions. The test is now commercially available in the United States. In the near future, it shall also enter the European market and be available in the company's clinical lab in Martinsried. “Understanding which fusion transcript is involved will be important as more targeted drugs become available.”, says Luis Raez, Memorial Cancer Institute, Fort Lauderdale, FL.
The lung cancer diagnostic is the first in a series of 2016 planned diagnostic test launches for Exosome Diagnostics. On ASCO 2016 Genitourinary Cancers Symposium earlier this year, the company presented data on a urine-based test for prostate cancer. The prospective clinical study showed that the non-invasive liquid biopsy with ExoDx™ Prostate accurately identified high-grade prostate cancer (HGPCA). The data support Exosome Diagnostic’s plan to develop a test for monitoring at-risks patients.
”Having recently launched the world’s first exosomal RNA based liquid biopsy, ExoDxTMLung(ALK), we are excited by these data, which validate the robustness of our platform technology in a second bio-fluid,” said John Boyce, President and Chief Executive Officer of Exosome Diagnostics.
The company has recently raised EURO 60 million new capital.
» Further information about Exosome Diagnostics